The Pfizer-BioNTech drug in two dosages According to a study published Friday by the US Food and Drug Administration, the COVID-19 vaccination is approximately 91 percent effective in avoiding symptomatic disease in young children and has no unanticipated safety risks.
According to the Associated Press, the agency posted its analysis of data from Pfizer’s pediatric study late Friday and stated that in nearly all models, the health benefits of administering kid-sized doses of the shot to America’s 28 million 5- to 11-year-olds far outweigh any potential side effects.
Pfizer Vaccine Prevents 91 Percent Of Symptomatic Covid In Children
Next Tuesday, the FDA will convene a panel of independent experts to provide advice on the use of the Pfizer vaccine in primary school-age children, and the agency’s decision might follow shortly after.
If the Centers for Disease Control and Prevention agrees, specialists at the CDC will provide more instructions on a vaccine rollout to children under the age of 12 – indicating that doses for young children might be provided as early as November, according to the Associated Press.
Children aged 12 and above currently have access to the Pfizer COVID-19 vaccine, but uptake by younger children might help avoid rare occurrences of symptomatic sickness as well as significantly reduce transmission, as children in this age range are regarded to be conduits.
The pediatric data presented by Pfizer to the FDA was mostly gathered in August and September, when the highly infectious Delta strain was already the prevalent type of virus in the United States, according to the Associated Press. Two doses of the vaccine proved to prevent 9 out of 10 episodes of symptomatic disease in young children, with no side effects other than aching arms, fever, and achiness.
The FDA stated that the trial population was insufficient to assess the risk of adverse effects such as myocarditis, a heart inflammation reported in extremely uncommon occurrences in adults.
According to the FDA, uptake of the vaccination by young children obviously saved many more hospitalizations than may have been caused by adverse effects in four distinct modeling scenarios.
According to the Associated Press, severe COVID in young infants is quite unusual. According to the most recent data from the American Academy of Pediatrics, almost 6.2 million American children have been infected with SARS-CoV-2, resulting in 630 fatalities in adults aged 18 and younger.
The Biden administration has already stockpiled millions of specially labeled pediatric doses of the Pfizer vaccine, which are ready for shipping throughout the country, according to the Associated Press. The vaccinations will be administered by almost 25,000 physicians and primary care practitioners.
While children have a lower risk of serious illness or death than adults, the CDC states that COVID-19 has killed over 630 Americans aged 18 and under. Approximately 6.2 million
More than 1.1 million children have been infected with the coronavirus in the preceding six weeks, according to the American Academy of Pediatrics, while the delta form has soared.
For the country’s 5- to 11-year-olds, the Biden administration has acquired enough kid-size doses in distinct orange-capped vials to distinguish them from adult vaccination. If the vaccine is approved, millions of doses, together with child-size needles, will be distributed around the country as quickly as feasible.
Over 25,000 physicians and primary care providers have already signed up to give the vaccines to youngsters.